Global Human Microbiome Modulators Market Research Report 2024

Publication ID:

PB505249978

Publication Date:

May 7, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The human microbiota is an aggregate of microorganisms residing in the human body, mostly in the gastrointestinal tract.
The global Human Microbiome Modulators market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Human Microbiome Modulators is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Human Microbiome Modulators is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Human Microbiome Modulators in Digestive Health is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Human Microbiome Modulators include Bayer, BioGaia, Chr. Hansen Holding, DowDuPont, Ingredion, ISOThrive, Jarrow Formulas, DSM and Lallemand, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Human Microbiome Modulators, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Microbiome Modulators.
Report Scope
The Human Microbiome Modulators market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Microbiome Modulators market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Microbiome Modulators companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer
BioGaia
Chr. Hansen Holding
DowDuPont
Ingredion
ISOThrive
Jarrow Formulas
DSM
Lallemand
Sanofi
Segment by Type
Probiotics and Creams
Prebiotics and Dietary Supplements
Drugs
Segment by Application
Digestive Health
Immune Health
Oral Health
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Human Microbiome Modulators companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Human Microbiome Modulators Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Probiotics and Creams
1.2.3 Prebiotics and Dietary Supplements
1.2.4 Drugs
1.3 Market by Application
1.3.1 Global Human Microbiome Modulators Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Digestive Health
1.3.3 Immune Health
1.3.4 Oral Health
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Human Microbiome Modulators Market Perspective (2019-2030)
2.2 Human Microbiome Modulators Growth Trends by Region
2.2.1 Global Human Microbiome Modulators Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Human Microbiome Modulators Historic Market Size by Region (2019-2024)
2.2.3 Human Microbiome Modulators Forecasted Market Size by Region (2025-2030)
2.3 Human Microbiome Modulators Market Dynamics
2.3.1 Human Microbiome Modulators Industry Trends
2.3.2 Human Microbiome Modulators Market Drivers
2.3.3 Human Microbiome Modulators Market Challenges
2.3.4 Human Microbiome Modulators Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Human Microbiome Modulators Players by Revenue
3.1.1 Global Top Human Microbiome Modulators Players by Revenue (2019-2024)
3.1.2 Global Human Microbiome Modulators Revenue Market Share by Players (2019-2024)
3.2 Global Human Microbiome Modulators Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Human Microbiome Modulators Revenue
3.4 Global Human Microbiome Modulators Market Concentration Ratio
3.4.1 Global Human Microbiome Modulators Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Human Microbiome Modulators Revenue in 2023
3.5 Human Microbiome Modulators Key Players Head office and Area Served
3.6 Key Players Human Microbiome Modulators Product Solution and Service
3.7 Date of Enter into Human Microbiome Modulators Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Human Microbiome Modulators Breakdown Data by Type
4.1 Global Human Microbiome Modulators Historic Market Size by Type (2019-2024)
4.2 Global Human Microbiome Modulators Forecasted Market Size by Type (2025-2030)
5 Human Microbiome Modulators Breakdown Data by Application
5.1 Global Human Microbiome Modulators Historic Market Size by Application (2019-2024)
5.2 Global Human Microbiome Modulators Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Human Microbiome Modulators Market Size (2019-2030)
6.2 North America Human Microbiome Modulators Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Human Microbiome Modulators Market Size by Country (2019-2024)
6.4 North America Human Microbiome Modulators Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Human Microbiome Modulators Market Size (2019-2030)
7.2 Europe Human Microbiome Modulators Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Human Microbiome Modulators Market Size by Country (2019-2024)
7.4 Europe Human Microbiome Modulators Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Human Microbiome Modulators Market Size (2019-2030)
8.2 Asia-Pacific Human Microbiome Modulators Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Human Microbiome Modulators Market Size by Region (2019-2024)
8.4 Asia-Pacific Human Microbiome Modulators Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Human Microbiome Modulators Market Size (2019-2030)
9.2 Latin America Human Microbiome Modulators Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Human Microbiome Modulators Market Size by Country (2019-2024)
9.4 Latin America Human Microbiome Modulators Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Human Microbiome Modulators Market Size (2019-2030)
10.2 Middle East & Africa Human Microbiome Modulators Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Human Microbiome Modulators Market Size by Country (2019-2024)
10.4 Middle East & Africa Human Microbiome Modulators Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bayer
11.1.1 Bayer Company Detail
11.1.2 Bayer Business Overview
11.1.3 Bayer Human Microbiome Modulators Introduction
11.1.4 Bayer Revenue in Human Microbiome Modulators Business (2019-2024)
11.1.5 Bayer Recent Development
11.2 BioGaia
11.2.1 BioGaia Company Detail
11.2.2 BioGaia Business Overview
11.2.3 BioGaia Human Microbiome Modulators Introduction
11.2.4 BioGaia Revenue in Human Microbiome Modulators Business (2019-2024)
11.2.5 BioGaia Recent Development
11.3 Chr. Hansen Holding
11.3.1 Chr. Hansen Holding Company Detail
11.3.2 Chr. Hansen Holding Business Overview
11.3.3 Chr. Hansen Holding Human Microbiome Modulators Introduction
11.3.4 Chr. Hansen Holding Revenue in Human Microbiome Modulators Business (2019-2024)
11.3.5 Chr. Hansen Holding Recent Development
11.4 DowDuPont
11.4.1 DowDuPont Company Detail
11.4.2 DowDuPont Business Overview
11.4.3 DowDuPont Human Microbiome Modulators Introduction
11.4.4 DowDuPont Revenue in Human Microbiome Modulators Business (2019-2024)
11.4.5 DowDuPont Recent Development
11.5 Ingredion
11.5.1 Ingredion Company Detail
11.5.2 Ingredion Business Overview
11.5.3 Ingredion Human Microbiome Modulators Introduction
11.5.4 Ingredion Revenue in Human Microbiome Modulators Business (2019-2024)
11.5.5 Ingredion Recent Development
11.6 ISOThrive
11.6.1 ISOThrive Company Detail
11.6.2 ISOThrive Business Overview
11.6.3 ISOThrive Human Microbiome Modulators Introduction
11.6.4 ISOThrive Revenue in Human Microbiome Modulators Business (2019-2024)
11.6.5 ISOThrive Recent Development
11.7 Jarrow Formulas
11.7.1 Jarrow Formulas Company Detail
11.7.2 Jarrow Formulas Business Overview
11.7.3 Jarrow Formulas Human Microbiome Modulators Introduction
11.7.4 Jarrow Formulas Revenue in Human Microbiome Modulators Business (2019-2024)
11.7.5 Jarrow Formulas Recent Development
11.8 DSM
11.8.1 DSM Company Detail
11.8.2 DSM Business Overview
11.8.3 DSM Human Microbiome Modulators Introduction
11.8.4 DSM Revenue in Human Microbiome Modulators Business (2019-2024)
11.8.5 DSM Recent Development
11.9 Lallemand
11.9.1 Lallemand Company Detail
11.9.2 Lallemand Business Overview
11.9.3 Lallemand Human Microbiome Modulators Introduction
11.9.4 Lallemand Revenue in Human Microbiome Modulators Business (2019-2024)
11.9.5 Lallemand Recent Development
11.10 Sanofi
11.10.1 Sanofi Company Detail
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Human Microbiome Modulators Introduction
11.10.4 Sanofi Revenue in Human Microbiome Modulators Business (2019-2024)
11.10.5 Sanofi Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Bayer
BioGaia
Chr. Hansen Holding
DowDuPont
Ingredion
ISOThrive
Jarrow Formulas
DSM
Lallemand
Sanofi

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂